Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design.
Int J Epidemiol
; 50(4): 1124-1133, 2021 08 30.
Article
in English
| MEDLINE | ID: covidwho-1387893
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
BACKGROUND:
The impact of SARS-CoV-2 alongside influenza is a major concern in the northern hemisphere as winter approaches.METHODS:
Test data for influenza and SARS-CoV-2 from national surveillance systems between 20 January 2020 and 25 April 2020 were used to estimate influenza infection on the risk of SARS-CoV-2 infection. A test-negative design was used to assess the odds of SARS-CoV-2 in those who tested positive for influenza compared with those who tested negative. The severity of SARS-CoV-2 was also assessed using univariable and multivariable analyses.RESULTS:
The risk of testing positive for SARS-CoV-2 was 58% lower among influenza-positive cases and patients with a coinfection had a risk of death of 5.92 (95% confidence interval 3.21-10.91) times greater than among those with neither influenza nor SARS-CoV-2. The odds of ventilator use or death and intensive care unit admission or death were greatest among coinfected patients.CONCLUSIONS:
Coinfection of these viruses could have a significant impact on morbidity, mortality and health-service demand.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Influenza, Human
/
Coinfection
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Int J Epidemiol
Year:
2021
Document Type:
Article
Affiliation country:
IJE
Similar
MEDLINE
...
LILACS
LIS